Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vericel Corp VCEL

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic... see more

Recent & Breaking News (NDAQ:VCEL)

Vericel Reports Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire October 24, 2024

Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

GlobeNewswire August 29, 2024

Vericel Announces FDA Approval and Commercial Availability of MACI Arthro

GlobeNewswire August 26, 2024

Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns

GlobeNewswire August 15, 2024

Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024

GlobeNewswire August 7, 2024

Vericel Reports Second Quarter 2024 Financial Results

GlobeNewswire August 1, 2024

Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

GlobeNewswire July 22, 2024

Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024

GlobeNewswire July 18, 2024

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

GlobeNewswire June 11, 2024

Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

GlobeNewswire May 22, 2024

Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance

GlobeNewswire May 8, 2024

Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024

GlobeNewswire April 24, 2024

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance

GlobeNewswire February 29, 2024

Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024

GlobeNewswire February 27, 2024

Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024

GlobeNewswire February 15, 2024

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

GlobeNewswire February 5, 2024

Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results

GlobeNewswire January 9, 2024

Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024

GlobeNewswire January 3, 2024

Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

GlobeNewswire November 8, 2023